scholarly journals Health Technology Assessment System in Sweden

2019 ◽  
pp. 16-23
Author(s):  
Vitaly Vladimirovich Omelyanovskiy ◽  
Filipp Vasilievich Gorkavenko ◽  
Yegor Sergeevich Saybel ◽  
Georgii Rubenovich Khachatryan
Keyword(s):  
Health Technology Assessment ◽  
Social Services ◽  
Technology Assessment ◽  
Medical Technology ◽  
Health Technology ◽  
Assessment System ◽  
Reimbursement System ◽  
Medical Technologies ◽  
The World ◽  
Regulatory Functions

Sweden is one of the first countries who establish health technology assessment (HTA) agency. Nowadays, there are two HTA organizations in the country. The first is one of the oldest in the world – the Swedish agency for health technology assessment and assessment of social services (SBU), and the second is the Council The Dental and Pharmaceutical Benefits Agency (TLV). Having similar tasks, organizations are created for different purposes. TLV assesses medical technologies within state reimbursement system, its purpose is to ensure the efficient use of budget funds. The SBU does not participate in the reimbursement system and does not have any regulatory functions, its purpose is to respond to public inquiries regarding the use of any medical technology. Agencies differ in the number of annually published reports, their types and objects of evaluation. Wherein the work of both institutions is characterized by a wide involvement of independent experts, outside organizations and particular attention to the economic component of the assessment.

scholarly journals Strategiczny model funkcjonalny z koordynującą rolą Regionalnego Centrum Oceny Inwestycji wspartego przez Narodowy Fundusz Zdrowia oraz Agencję Oceny Technologii Medycznych i Taryfikacji – model mieszany

2021 ◽  
Vol 18 (4) ◽  
pp. 298-309
Author(s):  
Małgorzata Gałązka-Sobotka ◽  
Iwona Kowalska-Bobko
Keyword(s):  
Health Technology Assessment ◽  
Technology Assessment ◽  
Medical Technology ◽  
Public Funding ◽  
Functional Model ◽  
Health Technology ◽  
Mixed System ◽  
Medical Technologies ◽  
Hospital Units ◽  
Tariff System

Mixed functional model HB-HTA with the coordinating role of the Regional Center for Investments supported by the Polish National Fund and Agency for Health Technology Assessment and Tariff System The implementation of the strategic model for hospital health technology assessment in Poland requires the involvement of many stakeholders. HB-HTA fundamentally concerns hospitals and how they rationalize decision making in implementing innovative medical technologies. However, the need to obtain public funding after verifying the effectiveness of a given medical technology or to keep up with the evolving HB-HTA method­ology naturally requires the involvement of both the payer (NFZ) and the Agency for Health Technology Assessment and Tariff System in activities connected with the implementation and development of HB-HTA. An important aspect of the coordination of activities in relation to hospital HTA is also the support given to hospitals by regional authorities – competent health departments in voivodeship offices – by assessing HB-HTA reports prepared by the hospitals and indicating regional competitive potential of a given medical technology. This creates a hybrid/mixed system of insti­tutional support for innovative medical technologies implemented in hospitals. This institutional plurality within HB-HTA is a clear asset, strengthening the hospital’s planned undertaking substantively and financially, especially when the assistance mechanisms undertaken are flexible, soft in nature, and allow hospital units to shape effective HB-HTA activities.

PP206 Health Technology Assessment Guidance In The United Kingdom: Addressing Issues Specific To Medical Devices

2021 ◽  
Vol 37 (S1) ◽  
pp. 26-26
Author(s):  
Scott Gibson ◽  
Sita Saunders ◽  
Amanda Hansson Hedblom ◽  
Maximilian Blüher ◽  
Rafael Torrejon Torres ◽  
...  
Keyword(s):  
United Kingdom ◽  
Health Technology Assessment ◽  
Medical Devices ◽  
Technology Assessment ◽  
Healthcare Providers ◽  
Economic Assessment ◽  
Health Technology ◽  
Training Costs ◽  
Medical Technologies ◽  
The United Kingdom

IntroductionThe United Kingdom spends approximately GBP4.2 billion (USD5.6 billion; EUR4.7 billion) each year on medical devices, but healthcare providers receive little health technology assessment (HTA) guidance on cost-effective device procurement. Our objective was to assess the availability of HTA guidance for medical technologies and to identify key challenges related to the economic assessment of these technologies.MethodsNational Institute for Health and Care Excellence technology appraisal (TA) and Medical Technologies Evaluation Programme (MTEP) appraisals published online between November 2009 and October 2020 were identified. The “case for adoption” recommendation, type of devices, and critiques of economic analyses for each MTEP appraisal were extracted and categorized.ResultsIn comparison to 415 publicly available TAs for pharmaceuticals, only 45 medical technologies have been appraised through the MTEP. MTEP-submitted technologies can be categorized into diagnostic (7), monitoring (3), prophylaxis (5), therapeutic (28), and other (2). Furthermore, 11 were implants, seven were used by patients, and 27 had provider interaction. Major points of MTEP criticism were a failure to model cost consequences, training costs, and organizational impact. There was also the barrier of transferring costs across budgeting divisions.ConclusionsIn comparison to HTA guidance for pharmaceuticals, there is a dearth of medical device guidance. Therapeutic and implantable devices appear to be disproportionately overrepresented in the MTEP process. This may be because their appraisal is most akin to pharmaceuticals, for which HTA processes are well established. To encourage more HTAs of medical devices, HTA guidance should elaborate on issues specifically related to medical devices.

PP142 A Mental Health Hospital-based Health Technology Assessment In Quebec, Canada: Structure And Products

2017 ◽  
Vol 33 (S1) ◽  
pp. 137-138
Author(s):  
Ionela Gheorghiu ◽  
Alain Lesage ◽  
Adam Mongodin ◽  
Marlène Galdin
Keyword(s):  
Mental Health ◽  
Decision Making ◽  
Health Technology Assessment ◽  
Social Services ◽  
Technology Assessment ◽  
Literature Search ◽  
New Technologies ◽  
Psychiatric Patients ◽  
Health Technology ◽  
Decision Making Process

INTRODUCTION:Our Hospital-based Health Technology Assessment unit (HB-HTA) was founded in 2011 following the nomination of Louis-H. Lafontaine hospital as the Montreal University Mental Health Institute (IUSMM). From the beginning, the HB-HTA has been supporting and advising the Chief Executive Officer of IUSMM in the decision-making process concerning the implementation of new technologies and practices in mental health. Since 2015, the HB-HTA is part of the East of Montreal Regional Integrated Health and Social Services Centre (CIUSSS de l'Est-de-l’Île de Montréal), continuing to support decisions in mental health. Currently, the HB-HTA unit is nested in the Quality, Performance and Ethics department.METHODS:Formed by a coordinator, a scientific advisor and a manager, the HB-HTA team plans, organizes and sets up the evaluation activities. The unit benefits from the support of a Steering Committee which consists of representatives of clinical, administrative and research directions, as well as of health users and families. This committee determine the strategic orientation of the HB-HTA unit, prioritize the projects, approves the evaluation products and gives indications on the knowledge transfer process.RESULTS:To answer the decision questions, our HB-HTA unit employs two types of products: evaluation reports and informative notes. Based on an exhaustive literature search and consultations with stakeholders, the evaluation reports offer recommendations to support the decision-making process. The informative notes are rapid responses based on a partial literature search. The nature of this type of analysis does not allow the formulation of recommendations, however, a conclusion of the consulted literature is offered.CONCLUSIONS:Based on the work of our HB-HTA unit, some important decisions were made by the IUSMM. As an example, the systematic screening of psychiatric patients for drug and alcohol was not favored by our institution; rather than this, priority was given to staff training, in order to better identify and treat psychiatric patients with substance abuse comorbidity.

scholarly journals THE VULNERABLE ASPECTS OF APPLICATION OF “HEALTH TECHNOLOGY ASSESSMENT”

2015 ◽  
Vol 31 (3) ◽  
pp. 197-198 ◽  
Author(s):  
Reza Dehnavieh ◽  
Somayeh Noori Hekmat ◽  
Sara Ghasemi ◽  
Nadia Mirshekari
Keyword(s):  
Health Technology Assessment ◽  
Technology Assessment ◽  
Health Technology ◽  
Developed Countries ◽  
Economic Outcomes ◽  
The Other ◽  
Ethical Aspects ◽  
Health Technologies ◽  
Other Hand ◽  
The World

Many countries in the world have tried to examine the possible methods for import and logical use of health technologies to manage their budgets on one hand and to prevent the entry of uncertain, inefficient, and insecure technologies on the other hand (1). The “health technology assessment” (HTA) is one of the dominant methods in most developed countries (2). HTA is a multidisciplinary field which studies the medical, social, and ethical aspects, as well as economic outcomes of production, diffusion, and application of health technologies (3).

A NEW HEALTH TECHNOLOGY ASSESSMENT SYSTEM FOR JAPAN? SIMULATING THE POTENTIAL IMPACT ON THE PRICE OF SIMEPREVIR

2017 ◽  
Vol 33 (1) ◽  
pp. 121-127 ◽  
Author(s):  
Jörg Mahlich ◽  
Isao Kamae ◽  
Bruno Rossi
Keyword(s):  
Health Technology Assessment ◽  
Technology Assessment ◽  
Health Technology ◽  
Cost Utility ◽  
Assessment System ◽  
Unit Price ◽  
Public Healthcare ◽  
Pricing Scheme ◽  
Potential Impact ◽  
Japanese Yen

Objectives:Japanese authorities have announced a plan to introduce a health technology assessment (HTA) system in 2016. This study assessed the potential impact of such a policy on the price of the antivirologic drug simeprevir.Methods:Taking the antivirologic drug simeprevir as an example, we compared the current Japanese price with hypothetical prices that might result if a U.K. (cost-utility) or German (efficiency frontier) style HTA assessment was in place.Results:The simeprevir unit price under the current Japanese pricing scheme is 13,122 Japanese yen (equivalent to 109.35 U.S. dollars as of April 2015). Depending on the selection of comparators and the pricing method, and assuming that HTA will be used as a basis for price setting, the estimated prices of simeprevir vary up to four times higher than under the current Japanese pricing scheme.Conclusions:Although the analysis is based on only one drug, it cannot be taken for granted that a new HTA system would reduce public healthcare expenditure in Japan.

Commentary on the article “Key principles for the improved conduct of health technology assessments for resource allocation decisions”

2008 ◽  
Vol 24 (03) ◽  
pp. 362-365 ◽  
Author(s):  
H. David Banta
Keyword(s):  
Resource Allocation ◽  
Health Technology Assessment ◽  
Technology Assessment ◽  
Health Technology ◽  
The World ◽  
Allocation Decisions ◽  
Resource Allocation Decisions

The article “Key principles for the improved conduct of health technology assessments for resource allocation decisions” presents fifteen principles for health technology assessment. Many of these cannot be disputed, and application of the principles as stated would undoubtedly improve HTA as it is developing in the world at large. My question is, are these the most important principles? The document does not really try to answer this question.

Ethical perspectives on health technology assessment

2004 ◽  
Vol 20 (1) ◽  
pp. 71-76 ◽  
Author(s):  
Henk ten Have
Keyword(s):  
Health Technology Assessment ◽  
Technology Assessment ◽  
Medical Technology ◽  
Health Technology ◽  
Minor Role ◽  
Engineering Model ◽  
Ethical Aspects ◽  
A Value ◽  
Definition Of ◽  
A Minor

This study analyses why ethical aspects play a minor role in health technology assessment (HTA) studies, even when comprehensive approaches of technology assessment are advocated. Technology is often regarded as a value-neutral tool. At the same time, bioethics is dominated by an engineering model. Ethical contributions to evaluation of medical technology should go beyond issues of application in clinical practice and focus also on the definition of problems, the demarcation of technical and nontechnical issues, and the morally problematic implications of technologies.

Sign in / Sign up

Export Citation Format

Share Document